Michele Nanna, MD
Cardiovascular Disease · Bronx, NYNPI 1265538219
Payments from drug & device makers
Across 439 payments — averaging $804.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$111K
- Boehringer Ingelheim International GmbH$97K
- Boehringer Ingelheim Pharma GmbH & Co.kg$76K
- Bayer$20K
- Sanofi US Services Inc.$14K
- Boehringer Ingelheim$13K
- plus $22K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 25 | $110,576 |
| Boehringer Ingelheim International GmbH | 229 | $97,261 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 24 | $76,410 |
| Bayer | 11 | $19,540 |
| Sanofi US Services Inc. | 9 | $13,853 |
| Boehringer Ingelheim | 3 | $13,361 |
| Novartis | 14 | $12,085 |
| Amgen | 19 | $7,190 |
| Merck | 17 | $455 |
| AstraZeneca | 15 | $433 |
| Edwards Lifesciences | 9 | $393 |
| Pfizer | 10 | $236 |
| Lexicon Pharmaceuticals, Inc. | 6 | $215 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $183 |
| Amarin Pharma, Inc. | 9 | $174 |
| Azurity Pharmaceuticals, Inc. | 8 | $149 |
| Abbott | 6 | $135 |
| Arbor Pharmaceuticals, Inc. | 5 | $85 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Daiichi Sankyo Inc. | 3 | $78 |
| Johnson & Johnson | 2 | $58 |
| Inspire Medical Systems, Inc. | 1 | $44 |
| Philips North America LLC | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$353,105 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Bronx
- Luigi di BiaseBronx$2.5M
- Joseph HelftBronx$488K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.